Acadia Pharmaceuticals INC 10-Q quarterly reports

Acadia Pharmaceuticals reported robust product sales growth and significant net income increase in Q3 2025, driven by NUPLAZID and DAYBUE, while discontinuing a Phase 3 PWS program.

Acadia Pharmaceuticals reported increased product sales for Q2 2025 driven by NUPLAZID and DAYBUE, while net income declined due to higher operating expenses and tax liabilities, as the company advances its pipeline and navigates ongoing legal challenges.

Acadia Pharmaceuticals announces Q1 2025 financial results, highlighting revenue growth driven by increased sales of NUPLAZID and DAYBUE.

Acadia Pharmaceuticals saw revenue growth in Q3 2024, driven by increased sales of both NUPLAZID and DAYBUE, while also managing research and development expenses.

Acadia Pharmaceuticals reported a profitable second quarter of 2024, driven by significant revenue growth from both NUPLAZID and DAYBUE.

Acadia Pharmaceuticals saw a significant increase in revenue in the first quarter of 2024, driven by sales of both NUPLAZID and DAYBUE.